MIRA reports positive 7-day dog study for obesity drug SKNY-1; de-risks dose selection

MIRA PHARMACEUTICALS, INC.

SKNY-1 showed rapid oral absorption and dose-dependent systemic exposure in Beagle dogs over 7 days.
Plasma concentrations were comparable between male and female animals.
Data demonstrates dose-dependent response and systemic accumulation with repeated dosing.
Findings de-risk dose selection and support advancement toward GLP toxicology and IND-enabling studies.
SKNY-1 aims to preserve lean body mass while promoting weight reduction in obesity.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.